Ontology highlight
ABSTRACT:
SUBMITTER: Cuker A
PROVIDER: S-EPMC6950888 | biostudies-literature | 2020 Jan
REPOSITORIES: biostudies-literature
Cuker Adam A Bass Ann D AD Nadj Congor C Agius Mark A MA Steingo Brian B Selmaj Krzysztof W KW Thoits Timothy T Guerreiro Alexandre A Van Wijmeersch Bart B Ziemssen Tjalf T Meuth Sven G SG LaGanke Christopher C CC Thangavelu Karthinathan K Rodriguez Claudio E CE Baker Darren P DP Margolin David H DH Jannsens Ann A
Multiple sclerosis (Houndmills, Basingstoke, England) 20190220 1
<h4>Background</h4>Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) has been identified as a risk.<h4>Objective</h4>To examine ITP incidence, treatment, and outcomes during the clinical development of alemtuzumab for RRMS and discuss postmarketing experience outside clinical trials.<h4>Methods</h4>CAMMS223 and Comparison of Alemtuzumab and Rebif<sup>®</sup> Efficacy in Multiple Sclerosis (CARE-MS) I and II investigated ...[more]